Patents Examined by Stacy B. Chen
  • Patent number: 11958884
    Abstract: Methods and compositions are provided that can be used to modify the assembly activating protein (AAP)-dependence of an adeno-associated virus (AAV).
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: April 16, 2024
    Assignees: Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
    Inventors: Luk H. Vandenberghe, Anna Claire Maurer
  • Patent number: 11944681
    Abstract: The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: April 2, 2024
    Assignees: Duke University, University of Maryland
    Inventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, LaTonya Williams, Kevin J. Wiehe, Gilad Adi Ofek
  • Patent number: 11931399
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Grant
    Filed: December 12, 2022
    Date of Patent: March 19, 2024
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
  • Patent number: 11931406
    Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 19, 2024
    Assignees: CureVac SE, Sanofi Pasteur
    Inventors: Patrick Baumhof, Wolfgang Grosse, Edith Jasny, Thomas Kramps, Daniel Voss, Julia Dannenmaier, Valérie Lecouturier, Yves Girerd-Chambaz
  • Patent number: 11926861
    Abstract: The invention describes a method for determining how to stimulate, monitor and/or inhibit virus production in whole blood culture. The invention relates to a test kit for performing the method and to the use of a suitable blood sampling system. The system can be used to determine how to activate or target latently HIV-infected cells, for clinical management of HIV treatments and for personalized therapeutic strategies.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: March 12, 2024
    Inventor: Heidi Kay
  • Patent number: 11912757
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: February 27, 2024
    Assignee: HUMABS BIOMED SA
    Inventor: Davide Corti
  • Patent number: 11913074
    Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: February 27, 2024
    Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
  • Patent number: 11911456
    Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: February 27, 2024
    Assignee: Vactech Oy
    Inventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
  • Patent number: 11897939
    Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: February 13, 2024
    Assignees: The University of North Carolina at Chapel Hill, The Johns Hopkins University
    Inventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
  • Patent number: 11883486
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: January 30, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Patent number: 11872277
    Abstract: The present invention provides novel engineered Ebolavirus GP proteins and polypeptides, scaffolded vaccine compositions that display the engineered proteins, and polynucleotides encoding the engineered proteins and scaffolded vaccine compositions. The invention also provides methods of using such engineered Ebolavirus GP proteins and vaccine compositions in various therapeutic applications, e.g., for preventing or treating Ebolavirus infections.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: January 16, 2024
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu, Anshul Chaudhary, Ian Wilson
  • Patent number: 11844832
    Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites).
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: December 19, 2023
    Assignee: Najit Technologies, Inc.
    Inventors: Ian J. Amanna, Elizabeth A. Poore
  • Patent number: 11845777
    Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: December 19, 2023
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson
  • Patent number: 11827675
    Abstract: The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 28, 2023
    Assignee: Texas Tech University System
    Inventors: Himanshu Garg, Anjali Joshi
  • Patent number: 11807849
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding one or more inhibitory nucleic acids targeting SCNA or a portion thereof, TMEM106B or a portion thereof, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: November 7, 2023
    Assignee: Prevail Therapeutics, Inc.
    Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
  • Patent number: 11802146
    Abstract: This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: October 31, 2023
    Assignees: ModernaTX, Inc., Vanderbilt University
    Inventors: Sunny Himansu, James E. Crowe, Jr., Giuseppe Ciaramella
  • Patent number: 11786589
    Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: October 17, 2023
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
  • Patent number: 11786591
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: October 17, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 11779640
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: October 10, 2023
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
  • Patent number: 11767540
    Abstract: In a first aspect, the present invention relates to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof wherein a substitution of a wild type non-cysteine amino acid into a cysteine is present whereby the wild type non-cysteine amino acid is exposed on the outer surface of the capsid of an AAV particle. In a further aspect, a mutated AAV particle comprising the AAV capsid protein or fragment thereof according to the present invention is provided. In addition, a nucleic acid encoding the AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid or a gene string. In addition, a host cell containing the nucleic acid vector or the nucleic acid according to the present invention as well as a composition comprising at least an infectious (transducing) AAV particle containing a mutated AAV capsid protein as defined herein together with a non-infectious AAV particle containing a mutated AAV capsid protein as e.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 26, 2023
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEW ANDTEN FORSCHUNG E.V.
    Inventors: Hildegard Büning, Anke Huber, Luca Perabo